Efficacy analysis of flumatinib combined with venetoclax-based regimen in 6 cases with Philadelphia chromosome-positive leukemias
Objectives:To evaluate the efficacy of flumatinib combined with venetoclax-based regimen in the treatment of patients with Philadelphia chromosome-positive(Ph+)leukemias.Methods:A total of 6 patients with Ph+leukemias were enrolled from February 2021 to April 2022 at the First Affiliated Hospital of Soochow University.The efficacy and safety of flumatinib combined with venetoclax-based regimen were analyzed retrospectively.Results:A total of 6 patients with Ph+leukemias were enrolled in this study.1 patients was initially diagnosed with Ph+acute myeloid leukemia(AML)and 3 were initially diagnosed with Ph+mixed phenotype acute leukemia(MPAL),1 patients had chronic myeloid leukemia at myeloid blastic phase(CML-MBP),and 1 Ph+AML patients had relapsed to prior therapy.Moreover,1 patients were treated with flumatinib and venetoclax,5 of 6 patients were treated with flumatinib,venetoclax and HMA regimens.The ORR after 1 cycle was 100%(4 CR,1 CRi,1 MLFS),and a complete molecular response(CMR)was achieved in 1 case,major molecular response(MMR)was achieved in 3(50%)patients,2 case didn't achieve MMR.In addition,four patients achieved a complete cytogenic response(CCyR)among 4 evaluable patients.Five patients were successfully bridged to allogeneic hematopoietic stem cell transplantation(allo-HSCT).Five patients were in continuous complete remission within the duration of follow-up to January 2024 and 1 patient was lost to follow-up.Conclusion:The combination of flumatinib and venetoclax-based regimen for the treatment of Ph+leukemias is effective and well tolerated.